OpenLM for Pharmaceuticals

Get the dosage right on your R&D software spend

From molecular modeling to process simulation and facility engineering, get complete usage visibility into your scientific and engineering software toolchain.

€60 billion

Estimated pharma R&D spend in Europe in 2025

Number links to source: EFPIA Key Data 2026

€287 billion

R&D invested by health industries worldwide in 2024, which is 19.9% of global business R&D

Number links to source: EU Industrial R&D Scoreboard 2025, via EFPIA

125,000

Estimated people employed in pharma R&D in Europe in 2025
Number links to source: EFPIA Key Data 2026

See your own pharmaceutical license usage in a live OpenLM demo.


By submitting this form you are agreeing to receive additional communications from OpenLM. Your information will be processed in accordance with our Privacy Policy

Start Free Trial

Trusted by leading innovators

Problem statement Your most expensive R&D software is also your least tracked

The "just in case" buffer

License counts are set at renewal and rarely revisited. Seats bought for the last program stay on the books long after it is cleared or shelved.

Pipeline peaks leave idle seats behind

Modeling, simulation and scale-up work surges around stage gates, then eases off. Licenses sized for the peak sit unused in between.

R&D budgets keep climbing

Health industries account for 19.9% of global business R&D, and European pharma R&D is estimated at €60 billion in 2025. As budgets grow, every idle modeling or simulation seat costs more. Without usage data, you can’t tell which seats earn their keep.

Where it breaks Where license gaps hit a yard

DISCOVERY AND DEVELOPMENT

Deadline risk

No seat is free when a study readout or regulatory submission can’t slip.

MULTI-SITE

Duplicated spend

Research labs, pilot plants and partner sites each hold their own licenses.

PROJECT COSTING

No cost visibility

Software costs are estimated per program, not allocated from real usage.

RENEWALS

Weak leverage

The vendor arrives with usage data. Most R&D teams don’t.

Case studies Pharmaceutical and Engineering: Software Case Studies

Pharmaceutical teams rely on tools like Ansys, Altair and Siemens to model, simulate and engineer. These licensed applications are costly and in uneven demand, so knowing how they are really used matters. The following are examples from engineering teams that show what visibility can do.

>€10,000

saved in the first year

After a corporate separation cut access to a shared Ansys pool, usage data showed where seats were hoarded. Peak demand fell from 155 to 140.

Siemens NX Medical devices

Read the case study →

$20,000+

saved per year, with ROI in 6 months

About 1,000 users of scientific software needed clear visibility into how licenses were used. OpenLM usage data cut annual licensing cost.

Scientific software Higher education

Read the case study →

bakerhughes

$50,000+

saved in 30 days

Shared Ansys capacity was lost, and usage data showed where seats were hoarded. Peak demand fell from 155 seats to 90 to 100.

Ansys Energy

Read the case study →

Usage visibility See usage vs. idle time

Session-level tracking

Track checkout, active and idle time per user, project and feature across 100+ license managers.

Automated idle harvesting

Set idle thresholds. Unused seats return to the pool without a ticket.

Per-project breakdown

Roll usage up by user, team or programme. Feed it straight into cost accounting.

usage vs. idle time
Project_Usage

Multi-site control One console, every lab, every program

Multi-site pooling

Replace separate site-by-site management with one shared view of design offices, depots and partner sites.

Programme-level cost data

Tie usage to project or contract codes so engineering software costs follow the work that drives them.

Reporting in minutes

Turn manual spreadsheet exports into scheduled reports for IT, engineering leads and finance.

Renewals Negotiate renewals with data, not guesses

Gap analysis

See where you are over-licensed or short of capacity, by product and site.

Audit readiness

Keep usage history on hand, so an audit request is a report, not a scramble.

True-up protection

Continuous monitoring keeps entitlements matched to peak usage.

Entitlement_license_usage

License denials Every denied seat is a study that didn't run

Spot the pattern

Find the tools and time windows that cause the most denials.

Quantify the cost

Track denial duration and turn it into a figure engineering and finance both accept.

Fewer denials, not fewer seats

Idle seats go back to the pool before the next engineer asks.

OpenLM LicOps for HPC Run computational jobs only when the license is ready

LicOps checks each HPC job against your rules before it takes a machine. Jobs that fit start, the rest queue instead of failing at start-up, and every decision is logged with its reason.

Built for your pharmaceutical stack

Feature-level monitoring

100+ supported license managers, including FlexNet (FLEXlm), Sentinel RMS, DSLS, Autodesk and Bentley licensing:

Scientific computing
mnova_logo
Process & facility engineering
Simulation & process modeling

By team What changes, by team

TeamWithout OpenLMWith OpenLMOpenLM capability
IT / SAMLimited visibility across environmentsOne view of usage across on-prem, SaaS, cloud and HPCSaaS, Cloud & HPC Monitoring
IT / SAMIdle and underused licenses increase costsIdle seats and dongles are found and reclaimed for reuseHarvesting, Reclamation & Dongle Monitoring
IT / SAMLicense data is disconnected from IT workflowsLicense data flows into the IT workflows you already runITSM & MCP Integration
R&D and engineering leadsLicense denials and shortages disrupt workDenials are tracked and flagged before they stall a projectDenial Tracking & Alerts
R&D and engineering leadsDifficult to control license access Access is controlled by group, with usage visible per groupAccess Control & Group Usage
FinanceLicense data is difficult to turn into decisionsUsage turns into reports that inform renewals and subscriptionsAdvanced BI Reporting & Subscription Optimization
Executives and complianceLicense usage must support compliance and auditsUsage history and access records are ready when an audit asksUsage History, Access Records & Audit Reporting

FAQ Frequently Asked Questions

Which pharmaceutical tools can OpenLM monitor?

OpenLM supports 100+ license managers, including FlexNet (FLEXlm). That covers the scientific computing, simulation and process engineering tools R&D teams run on network licenses.

Not if you size from real data. Denial reports show when and where demand peaks, and idle harvesting returns unused seats to the pool before the next request.

Yes. Usage rolls up by user, team or project, so finance can allocate software costs to the programs that drive them.

Yes. Continuous monitoring gives you usage history by product and site, so you can compare entitlements against actual peak use before a vendor asks.

OpenLM is ISO/IEC 27001:2022 certified and SOC 2 Type II compliant. 

Your next R&D software renewal is already on the calendar

See what your license usage really looks like before the vendor sends the notice.